Abnormal c‐Met activation is reported in many types of solid tumors, including non‐small cell lung cancer (NSCLC),4, 5 ovarian cancer,6, 7 breast cancer,8 prostate cancer,9 and others.10, 11. This evidence concerns the gene MET and ovarian carcinoma.